Tkalcevic VI, Cuzic S, Brajsa K, et al
#GLP1 #Obesity #NovoNordisk #PharmaManufacturing #MetabolicHealth #LifeSciences Novo Nordisks 432M investment in Athlone is a clear signal that oral GLP1s are becoming the next competitive frontier in obesity care
Standard treatment protocols involve twice-weekly injections for 4-6 weeks, followed by maintenance therapy tailored to individual response and deficiency severity
Additionally, the duration of the weight loss effect is an important issue
But youre probably better off spending your money on whole food options instead
Where you land on it should be decided by your labs, your response, your body composition, and how you feel, with a provider who keeps adjusting instead of handing you a vial and disappearing